THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST

Santhera's Agamree Receives NICE Recommendation and China NMPA Approval for Duchenne Muscular Dystrophy Treatment

5 months ago

• The National Institute for Health and Care Excellence (NICE) has recommended Agamree (vamorolone) for treating Duchenne muscular dystrophy (DMD) in patients aged four and older in England, Wales, and Northern Ireland. • China's National Medical Products Administration (NMPA) has approved Agamree for DMD, marking it as the first approved treatment for the condition in China. • Agamree demonstrated clinically significant safety benefits, including better bone metabolism and growth, compared to standard corticosteroids in clinical trials. • Santhera is collaborating with NHS and Sperogenix Therapeutics to ensure rapid patient access to Agamree in the UK and China, respectively.